All In Biotech

Drug Trial Radar · NCT07282483

Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients

Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

Mar 16, 2026

Primary completion

Oct 25, 2026

Study completion Dec 25, 2026

Sponsor

Lead sponsor
West China HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy and safety of traditional Chinese medicine oral liquid and mouthwash in the treatment of radiotherapy induced oral mucositis in patients with head and neck malignancies

Conditions

  • Radiation-induced Oral Mucositis

Interventions

  • Qingying oral liquid and modified Da Huang-Huang Lian Xiexin mouthwashDrug

    Classical traditional Chinese medicine (TCM) formulations provided as an oral liquid and a herbal mouthwash

  • Placebo oral solution and mouthwashDrug

    A placebo matched in color, odor, and taste to the Qingying oral liquid and the modified Da Huang-Huang Lian Xiexin mouthwash, but containing no active medicinal ingredients.

  • radiotherapyRadiation

    All subjects underwent radical radiotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate of severe oral mucositis (RTOG grade ≥ 3)Time frame: From the start of radiotherapy to 8 weeks after the end of radiotherapy. The evaluation period is approximately 14 to 14.5 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.